HIV-1 infection and cognitive impairment in the cART era: a review.

Abstract

With the introduction of combination antiretroviral therapy AIDS dementia complex or HIV-associated dementia, as it was termed later, largely disappeared in clinical practice. However, in the past few years, patients, long-term infected and treated, including those with systemically well controlled infection, started to complain about milder memory problems and slowness, difficulties in concentration, planning, and multitasking. Neuropsychological studies have confirmed that cognitive impairment occurs in a substantial (15-50%) proportion of patients. Among HIV-1-infected patients cognitive impairment was and is one of the most feared complications of HIV-1 infection. In addition, neurocognitive impairment may affect adherence to treatment and ultimately result in increased morbidity for systemic disease. So what may be going on in the CNS after so many years of apparently controlled HIV-1 infection is an urgent and important challenge in the field of HIV medicine. In this review we summarize the key currently available data. We describe the clinical neurological and neuropsychological findings, the preferred diagnostic approach with new imaging techniques and cerebrospinal fluid analysis. We try to integrate data on pathogenesis and finally discuss possible therapeutic interventions.

• Authors: Judith Schouten, Paola Cinque, Magnus Gisslen, Peter Reiss, Peter Portegies
• Journal: AIDS (London, England) (AIDS) Vol. 25 Issue 5 Pg. 561-75 (Mar 13 2011) ISSN: 1473-5571 [Electronic] England
• PMID: 21160410 (Publication Type: Editorial, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Anti-Retroviral Agents

Topics

• AIDS Dementia Complex (cerebrospinal fluid, diagnosis, drug therapy)
• Administration, Inhalation
• Anti-Retroviral Agents (therapeutic use)
• HIV Infections (cerebrospinal fluid, drug therapy)
• HIV-1
• Humans
• Neuropsychological Tests
• Risk Factors
• Terminology as Topic